Alexandria Real Estate Equities, Inc. announced financial and operating results for the third quarter ended September 30, 2020.
Key highlights |
YTD |
|||||||||||||||
Operating results |
3Q20 |
3Q19 |
3Q20 |
3Q19 |
||||||||||||
Total revenues: |
||||||||||||||||
In millions |
$ |
545.0 |
$ |
390.5 |
$ |
1,421.9 |
$ |
1,123.2 |
||||||||
Growth |
39.6% |
26.6% |
||||||||||||||
Net income (loss) attributable to Alexandria’s common stockholders – diluted |
||||||||||||||||
In millions |
$ |
79.3 |
$ |
(49.8) |
$ |
324.2 |
$ |
150.4 |
||||||||
Per share |
$ |
0.63 |
$ |
(0.44) |
$ |
2.61 |
$ |
1.35 |
||||||||
Funds from operations attributable to Alexandria’s common stockholders – diluted, as adjusted |
||||||||||||||||
In millions |
$ |
230.7 |
$ |
197.1 |
$ |
677.1 |
$ |
579.6 |
||||||||
Per share |
$ |
1.83 |
$ |
1.75 |
$ |
5.46 |
$ |
5.19 |
Alexandria and its tenants at the vanguard and heart of the life science ecosystem
Bringing together our unique and pioneering strategic vertical platforms of essential Labspace® real estate, strategic venture investments, impactful thought leadership, and purposeful corporate responsibility, Alexandria is at the vanguard and heart of the vital life science ecosystem that is advancing solutions for COVID-19 and other key challenges to human health. Safe and effective vaccines and therapies, in addition to widespread testing, continue to be critically needed to combat the global COVID-19 pandemic. By maintaining continuous operations across our campuses and facilities, Alexandria has enabled our tenants, nearly 100 of which have programs focused on COVID-19, to continue to pursue their essential, mission-critical research, development, manufacturing, and commercialization efforts. Refer to “Alexandria and Its Innovative Tenants Are at the Vanguard and Heart of the Life Science Ecosystem Advancing Solutions for COVID-19″ of this Earnings Press Release for additional detail.
Strong and flexible balance sheet with significant liquidity
Continued dividend strategy to share growth in cash flows with stockholders
Common stock dividend declared for 3Q20 of $1.06 per common share, aggregating $4.18 per common share for the twelve months ended September 30, 2020, up 24 cents, or 6%, over the twelve months ended September 30, 2019. Our FFO payout ratio of 61% for the three months ended September 30, 2020, allows us to share growth in cash flows from operating activities with our stockholders while also retaining a significant portion for reinvestment.
A REIT industry-leading, high-quality tenant roster
Key strategic transactions generated capital for investment into our highly leased value-creation pipeline